



AhR Signaling
Linking diet and immunity

Learn more →

InvivoGen



The Chemokine Monocyte Chemotactic Protein 1 Triggers Janus Kinase 2 Activation and Tyrosine Phosphorylation of the CCR2B Receptor

This information is current as of November 13, 2019.

M. Mellado, J. M. Rodríguez-Frade, A. Aragay, G. del Real, A. M. Martín, A. J. Vila-Coro, A. Serrano, F. Mayor, Jr. and C. Martínez-A.

J Immunol 1998; 161:805-813; ;
<http://www.jimmunol.org/content/161/2/805>

References This article **cites 41 articles**, 25 of which you can access for free at:
<http://www.jimmunol.org/content/161/2/805.full#ref-list-1>

Why *The JI*? [Submit online.](#)

- **Rapid Reviews! 30 days*** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

*average

Subscription Information about subscribing to *The Journal of Immunology* is online at:
<http://jimmunol.org/subscription>

Permissions Submit copyright permission requests at:
<http://www.aai.org/About/Publications/JI/copyright.html>

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
<http://jimmunol.org/alerts>



The Chemokine Monocyte Chemoattractant Protein 1 Triggers Janus Kinase 2 Activation and Tyrosine Phosphorylation of the CCR2B Receptor¹

M. Mellado,^{2*} J. M. Rodríguez-Frade,^{2*} A. Aragay,^{2†} G. del Real,^{*} A. M. Martín,^{*} A. J. Vila-Coro,^{*} A. Serrano,^{*} F. Mayor, Jr.[†] and C. Martínez-A.^{3*}

The chemokines are a growing family of low m.w., 70- to 80-residue proinflammatory cytokines that operate by interacting with G protein-coupled receptors. Chemokines are involved in cell migration and in the activation of specific leukocyte subsets. Using the Mono Mac 1 monocytic cell line, we show that monocyte chemoattractant protein 1 (MCP-1) triggers activation of the Janus kinase 2 (JAK2)/STAT3 pathway and CCR2 receptor tyrosine phosphorylation. Both Ca²⁺ mobilization and cell migration are blocked in Mono Mac 1 cells by tyrphostin B42, a specific JAK2 kinase inhibitor. Within seconds of MCP-1 activation, JAK2 phosphorylates CCR2 at the Tyr¹³⁹ position and promotes JAK2/STAT3 complex association to the receptor. This MCP-1-initiated phosphorylation and association to JAK2 is also observed in CCR2B-transfected HEK293 cells. In contrast, when a CCR2B Tyr¹³⁹Phe mutant is expressed in HEK293 cells, it is not phosphorylated in tyrosine and triggers neither JAK2/STAT3 activation nor Ca²⁺ mobilization in response to MCP-1. These results implicate the tyrosine kinase pathway in early chemokine signaling, suggesting a key role for this kinase in later events. *The Journal of Immunology*, 1998, 161: 805–813.

Leukocyte migration to inflammation sites is a multistep process mediated by a series of sequential, but overlapping, interactions in which the generation of chemotactic gradients plays a key role. Chemotactic cytokines, or chemokines, are responsible for chemoattraction of specific subsets of leukocyte populations to inflammation sites (1, 2).

The chemokines are a growing family of low m.w., 70- to 80-residue proinflammatory cytokines, characterized by their ability to induce migration and activation of specific leukocyte population subsets (2–6). The two main branches of the family are distinguished by overall sequence homology, chromosomal location, and leukocyte population specificity (7). The CXC (α) chemokines act on neutrophils and nonhemopoietic cells involved in wound healing, whereas the CC (β) chemokines act on monocytes, eosinophils, basophils, NK cells, and different lymphocyte subpopulations (5, 6). New chemokine families have been identified recently, which maintain overall sequence homology but lack the typical cysteine distribution (C, or γ , and CX₃C, or δ , chemokines) (8, 9).

The CC chemokine monocyte chemoattractant protein 1 (MCP-1)⁴ was originally described as a potent chemoattractant for monocytes (10), produced by different cell types in response to a variety of mediators including PDGF (platelet-derived growth factor), TNF- α , LPS, and oxidized low density lipoproteins (11, 12). Since then, many other activities have been assigned to MCP-1, including induction of T cell migration (13), suppression of tumor growth in animal models (14), and neutralization of HIV-1 (15). MCP-1 has also been associated with several disease states in which monocyte infiltration plays a role, such as granulomatous disease, host responses to bacteria, rheumatoid arthritis, inflammatory heart disease, bone trauma, asthma, and sepsis (16, 17).

Chemokines activate their functions through interaction with single-chain, seven-helix membrane-spanning receptors coupled to G proteins (GPCR) (3). To date, nine receptors have been defined for the CC chemokines (18) and four for the CXC family, together with several putative CC or CXC receptors for which the ligands remain to be determined. They have an N terminus and three extracellular loops that act in concert to bind the chemokine ligand (19, 20), while the three intracellular loops and the C terminus are involved in transduction of the chemokine signal. The activation signals following chemokine stimulation are not well defined, and various signal transduction pathways have been implicated through the association of the chemokine receptors with guanine nucleotide-binding protein (G proteins) (21). In all cases, a pertussis toxin (PTX)-sensitive G protein was found, although there are also examples of PTX-insensitive G proteins, as is the case for the C5a receptor, which also couples to G α 16 (22). The biochemical signaling pathways include changes in intracellular cAMP levels (23), phospholipase activation (24), increases in tyrosine phosphorylation including the Src substrates focal adhesion kinase (p125^{FAK}) and ZAP-70 (25), increased association of Src family

*Department of Immunology and Oncology, Centro Nacional de Biotecnología, and †Departamento de Biología Molecular, Centro de Biología Molecular "Severo Ochoa," Consejo Superior de Investigaciones Científica (CSIC)-Universidad Autónoma de Madrid, Campus de Cantoblanco, Madrid, Spain

Received for publication October 2, 1997. Accepted for publication March 18, 1998.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported in part by grants from the Dirección General de Investigación Científica y Tecnológica (DGICYT)/PM95-0033 and the Fundación Ramón Areces to F.M., and by grants from the DGICYT and the European Union to C.M.-A. The Department of Immunology and Oncology was founded and is supported by the CSIC and Pharmacia and Upjohn.

² M.M., J.M.R.-F., and A.A. contributed equally to the work leading to the present manuscript.

³ Address correspondence and reprint requests to Dr. Carlos Martínez-A., Department of Immunology and Oncology, Centro Nacional de Biotecnología, Universidad Autónoma de Madrid, Campus de Cantoblanco, E-28049 Madrid, Spain. E-mail address: cmartinez@cnb.uam.es

⁴ Abbreviations used in this paper: MCP-1, monocyte chemoattractant protein 1; CTX, cholera toxin; EGF, epidermal growth factor; GPCR, G protein-coupled receptor; JAK, Janus kinase; PTX, pertussis toxin; PTyr, phosphotyrosine.

kinases with p21^{ras} (26), and activation of the MAPK (mitogen-activating protein kinase) cascade (27).

The cellular response resulting from the activation of a given chemokine receptor can vary depending on the cell in which it is expressed. This is presumably due to the availability of specific G protein subunits and other downstream effector molecules. It has recently been demonstrated that the association of chemokine receptors to different G proteins depends on the receptor and the cell line studied (28).

Biochemical analysis of chemokine signaling has been hampered by the low levels of receptor expression and by the promiscuity of individual receptors with various ligands. Using the CCR2 chemokine receptor as a model, we have analyzed early signaling events activated by MCP-1 binding in a human monocytic cell line (Mono Mac 1). MCP-1 triggers tyrosine phosphorylation and activation of the JAK2/STAT3 pathway in a PTX-independent manner. This MCP-1-initiated phosphorylation and association to JAK2 is also observed in CCR2B-transfected HEK293 cells. In contrast, when a CCR2B Tyr¹³⁹Phe mutant is expressed in HEK293 cells, it is not phosphorylated in tyrosine and triggers neither JAK2/STAT3 activation nor Ca²⁺ mobilization in response to MCP-1. Altogether, these data indicate that within seconds of activation, JAK2 phosphorylates CCR2 at the Tyr¹³⁹ position and promotes JAK2/STAT3 complex association to the receptor. The blockage of MCP-1-induced Ca²⁺ mobilization and cell migration in Mono Mac 1 cells treated with the specific JAK2 kinase inhibitor, tyrphostin B42 (29), demonstrates that JAK2 activation is one of the first events following ligand binding and assigns JAK2 a critical upstream role for all other signaling events, including the association between the receptor and the G proteins.

Materials and Methods

Biologic materials

Mono Mac 1 (DSM ACC252) and HEK293 cells (ATCC TIB202) were obtained from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany) and the American Type Culture Collection (ATCC, Manassas, VA), respectively. Abs used include monoclonal anti-Ptyr (4G10) and rabbit anti-JAK2 (Upstate Biotechnology, Lake Placid, NY); anti-G α_i , anti-STAT3, and anti-STAT5 (Santa Cruz Biotechnology, Santa Cruz, CA); anti-Ptyr (PY20) (Transduction Laboratories, Lexington, KY); anti-CD4 (HP2.6; kindly donated by Dr. A. C. Carrera), and anti-MHC class I (W6/32, ATCC). Anti-CCR2 mAb MCP-1R03 and MCP-1R05 were generated in our laboratory (15, 30). Epidermal growth factor (EGF)-stimulated A-431 cell lysates were from Upstate Biotechnology and MCP-1 from Peprotech (London, U.K.).

Flow cytometry analysis

Cells were centrifuged ($250 \times g$, 10 min, room temperature), plated in V-bottom 96-well plates (2.5×10^5 cells/well) and incubated with 50 μ l/well biotin-labeled mAb (5 μ g/ml, 60 min, 4°C). Cells were washed twice in PBS with 2% BSA and 2% FCS and centrifuged ($250 \times g$, 5 min, 4°C). FITC-labeled streptavidin (Southern Biotechnologies, Birmingham, AL) was added, cells incubated (30 min, 4°C), and plates washed twice. Cell-bound fluorescence was determined in a Profile XL flow cytometer at 525 nm (Coulter Electronics, Miami, FL).

Calcium determination

Changes in intracellular calcium concentration were monitored using the fluorescent probe Fluo-3, AM (Calbiochem, La Jolla, CA). Cells (2.5×10^6 cells/ml), untreated or treated for 16 h with either cholera toxin (CTX; 0.4 μ g/ml) or PTX (0.1 μ g/ml), were resuspended in RPMI containing 10% FCS and 10 mM HEPES and incubated with 10 μ l/10⁶ cells of Fluo-3, AM (300 μ M in DMSO) for 15 min at 37°C. After incubation, cells were washed and resuspended in complete medium containing 2 mM CaCl₂ and maintained at 4°C until just before MCP-1 addition, to minimize membrane trafficking and to eliminate spontaneous Ca²⁺ entry. Calcium mobilization in response to 5 nM MCP-1 (Peprotech) was determined at 37°C in an EPICS XL flow cytometer at 525 nm (Coulter), and included background level stabilization and determination of the level of probe




FIGURE 1. MCP-1 induction of Ca²⁺ mobilization and G α_i association to CCR2 receptor in Mono Mac 1 cells. *A*, 5 nM MCP-1-induced Ca²⁺ mobilization in Mono Mac 1 cells, untreated or preincubated with CTX or PTX, was determined at 525 nm in a flow cytometer. The result of one of three experiments performed is shown. Results are expressed as percentage of the maximum chemokine response. Equivalent Fluo-3, AM loading was determined as indicated in *Materials and Methods*. *B*, 5 nM MCP-1-induced Mono Mac 1 cell lysates were immunoprecipitated with anti-CCR2 (MCP-1R03), or anti-CD4 (HP2.6) Abs as control, and the Western blot developed with anti-G α_i Ab. As a control for the presence of equal amounts of CCR2 in the different lanes, the blot was stripped and developed with the anti-CCR2 Ab MCP-1R05. The arrow indicates the position of G α_i .




FIGURE 2. MCP-1-induced tyrosine phosphorylation and CCR2 receptor. MCP-1-induced (5 nM) Mono Mac 1 cell lysates were immunoprecipitated with anti-PTyr (PY20) and developed in Western blot with anti-CCR2 (MCP-1R05) (*upper panel*) or immunoprecipitated with anti-CCR2 (MCP-1R03) and developed with anti-PTyr (4G10) Abs (*lower panel*). As controls, an unstimulated, unprecipitated Mono Mac 1 cell lysate and a MCP-1-induced Mono Mac 1 cell lysate immunoprecipitated with anti-CD4 were analyzed in Western blot with anti-CCR2 (MCP-1R05) Ab. CCR2 protein loading was controlled by stripping and reprobing membranes with mAb MCP-1R05 (*lower panel*).

loaded for each sample. Only samples with a similar load, as assessed by determination of Ca^{2+} mobilization induced by an ionophore (ionomycin, 5 $\mu\text{g}/\text{ml}$; Sigma Chemicals, St. Louis, MO) are considered acceptable. When tyrphostin treatment was used, Mono Mac 1 cells were preincubated with 25 μM tyrphostin B42 or A1 (Calbiochem-Novabiochem, La Jolla, CA) for 12 h at 37°C as described (29).

Cell migration

Mono Mac 1 cells (0.5×10^6 cells/ml), untreated or preincubated with 25 μM tyrphostin B42 or A1 (Calbiochem) for 12 h at 37°C, 5% CO_2 in RPMI 1640 containing 10% FCS, were placed (0.25×10^6 cells in 0.1 ml) in the upper well of 24-well transmigration chambers (Transwell; Costar, Cambridge, MA), and 5 nM MCP-1 (diluted in 0.6 ml RPMI containing 0.25% BSA) was added to the lower well. Plates were incubated 120 min at 37°C, 5% CO_2 , and the cells that had migrated to the lower chamber were counted as described (15).

Transfection

Human HEK293 embryonic kidney cells were transfected with human CCR2B and CCR2BY139F cDNA cloned in pCDNAIII by the calcium phosphate precipitation method. Stably transfected cells were selected in G-418 (Life Technologies, Gaithersburg, MD) and screened in flow cytometry analysis for receptor expression using anti-CCR2 Abs. All experiments were performed using at least four cell lines for each plasmid.

Site-directed mutagenesis of CCR2B Tyr¹³⁹

Phenylalanine was substituted for tyrosine at residue 139 in the CCR2B receptor by overlap extension. Briefly, two primary PCR with overlapping ends were performed from the gene cloned in pUC18. One fragment encompasses positions 1 through 429 and the other, positions 405 through 1080 of the CCR2B gene. The sequence includes the target Tyr codon (TAC) at position 417, which was replaced with a phenylalanine codon (TTC). Primary PCR products were gel purified and Klenow treated to remove extra 3' bases. For secondary PCR, both primary fragments were mixed with primers including *Bam*HI and *Xho*I sites at the 5' ends. After 25 cycles, the assembled fragment (1080 bp) containing Phe at position 139 was gel purified, digested with *Bam*HI and *Xho*I enzymes, and cloned in pCDNA3 (Invitrogen, San Diego, CA). The presence of the Y139F mutation was confirmed by DNA sequencing.

Immunoprecipitation, SDS-PAGE, and Western blot analysis

MCP-1-stimulated cells (20×10^6) were lysed in a detergent buffer (20 mM triethanolamine, pH 8.0, 300 mM NaCl, 2 mM EDTA, 20% glycerol, 1% digitonin, with 10 μM sodium orthovanadate, 10 $\mu\text{g}/\text{ml}$ leupeptin, and 10 $\mu\text{g}/\text{ml}$ aprotinin) for 30 min at 4°C with continuous rocking, then centrifuged ($15,000 \times g$, 15 min). Immunoprecipitations were performed essentially as described earlier (31). Protein extracts precleared by incubation with 20 μg of anti-mouse IgG-agarose (Sigma Chemicals) or protein A-

Sepharose (60 min, 4°C) were centrifuged ($15,000 \times g$, 1 min), immunoprecipitated with the appropriate Ab (5 $\mu\text{g}/\text{sample}$, 120 min, 4°C), followed by anti-mouse IgG-agarose or protein A-Sepharose if the first Ab was derived from rabbit serum. Immunoprecipitates or protein extracts were separated in 12.5% SDS-PAGE and transferred to nitrocellulose membranes. Western blot analysis was performed as described (32), using 2% BSA in Tris-buffered saline (TBS) as blocking agent for the anti-PTyr analyses. When stripping was required, membranes were incubated for 60 min at 60°C with 62.5 mM Tris-HCl, pH 7.8, containing 2% SDS and 0.5% β -mercaptoethanol. After washing with 0.1% Tween 20 in TBS for 2 h, membranes were reblocked, reprobed with the appropriate Ab, and developed as described above. In all cases, protein loading was carefully controlled by using a protein detection kit (Pierce, Rockford, IL) and, when necessary, by reprobing the membrane with the immunoprecipitating Ab.

Results


The CCR2 receptor regulates calcium mobilization and couples to the G_i protein

The human monocytic cell line Mono Mac 1 expresses the MCP-1 chemokine receptor CCR2B (33). In response to MCP-1, these cells mobilize calcium (Fig. 1A), become desensitized to a second MCP-1 stimulus, and undergo cell migration (not shown). PTX treatment abrogates both calcium release and migration in response to MCP-1, whereas no effect was observed following incubation with CTX (Fig. 1A). This is consistent with other studies showing that some MCP-1 downstream signals in other monocyte lines and T cells are coupled to PTX-sensitive G proteins (28). Using a CCR2-specific mAb, MCP-1R03 (15, 30), we analyzed the physical association between the CCR2 receptor and the $G\alpha_i$ subunit of the heterotrimeric G protein. A CCR2 receptor-associated G_i protein was immunoprecipitated and detected in Western blot using an anti- $G\alpha_i$ -specific Ab (Fig. 1B). This association is initiated within 30 s of MCP-1 triggering, and persists for 5 min after chemokine binding. As occurs in other cell systems, the CCR2 receptor, therefore, regulates calcium release and couples to the G_i protein in Mono Mac 1 cells.

MCP-1 induces tyrosine phosphorylation of the CCR2 receptor

In MCP-1-activated Mono Mac 1 cells, a 38-kDa protein phosphorylated in tyrosine residues was initially identified as the CCR2 receptor (not shown). Cell lysates were immunoprecipitated with anti-PTyr and Western blots developed with anti-CCR2 receptor Abs (Fig. 2, *upper panel*) or precipitated with anti-CCR2 and

FIGURE 3. MCP-1-induced receptor association of JAK2 kinase. *A*, Mono Mac I cells were MCP-1 stimulated (5 nM), and lysates were immunoprecipitated with anti-CCR2 mAb and analyzed in Western blot with anti-JAK2 Ab. Control MCP-1-stimulated (5 nM) Mono Mac 1 cell lysates immunoprecipitated with anti-CD4 and analyzed with anti-JAK2 are shown. As a positive control, EGF-stimulated A431 cell lysates were tested in Western blot with the same anti-JAK2 Ab. CCR2 protein loading was controlled as described in Figure 2 (*lower panel*). *B*, PTX-treated Mono Mac 1 cells were MCP-1 stimulated as in *A*, lysates immunoprecipitated with anti-PTyr (PY20) and analyzed in Western blot with anti-CCR2 mAb. *C*, PTX-treated Mono Mac 1 cells were stimulated with MCP-1, lysed, and analyzed in Western blot as described for *A*.



developed with anti-PTyr Ab (Fig. 2, *lower panel*), while no differences were observed in the amount of CCR2 in each lane (Fig. 2, *lower panel*) when the same membrane was stripped and reblotted with anti-CCR2 Ab. The same phosphorylated 38-kDa band was observed in both cases, confirming phosphorylation of the CCR2 upon MCP-1 stimulation. An increase in CCR2 receptor phosphorylation is seen as early as 30 s after MCP-1 stimulation, and phosphorylation persists for 20 to 30 min, decreasing thereafter. We have observed residual phosphorylation of CCR2 in untreated cells (Fig. 2), the significance of which is discussed below.

MCP-1 induces rapid JAK-2 activation and association to the CCR2 in a PTX-independent manner

To ascertain which kinase is responsible for the rapid CCR2 chemokine receptor phosphorylation, Mono Mac 1 cells were stimulated with MCP-1, and cell lysates were immunoprecipitated with anti-CCR2 or anti-CD4 as an isotype-matched Ab control. Anti-JAK2 Abs identified a 130-kDa protein in the anti-CCR2 immunoprecipitate (Fig. 3A). Furthermore, JAK2 phosphorylated in tyrosine is observed after MCP-1 stimulation (Fig. 4A), while JAK2




FIGURE 4. MCP-1-induced tyrosine phosphorylation of JAK2 kinase. *A*, As described in the legend of Figure 2, cells were immunoprecipitated with anti-JAK2 and tested in Western blot with anti-Ptyr Ab. JAK2 protein loading was controlled by reprobing membranes with anti-JAK2 Ab. *B*, As described in Figure 2, cells were immunoprecipitated with anti-CCR2 mAb and analyzed in Western blot with anti-STAT3 or -STAT5 Abs. CCR2 protein loading was controlled as described before (*lower panel*). *C*, As in Figure 2, cells were immunoprecipitated with anti-Ptyr (PY20) and tested in Western blot with anti-Stat3 Ab.

levels are unchanged (Fig. 4A) as determined by stripping and reblotting the same membrane with anti-JAK2 Ab. JAK2 association to the CCR2 receptor takes place as early as 30 s after MCP-1 stimulation (Fig. 3A); small amounts of JAK2 were also found associated to the CCR2 receptor in the absence of added MCP-1, consistent with receptor phosphorylation in the absence of exogenous ligand in Mono Mac 1 cells. Immunoprecipitation of cell lysates with isotype-matched control Abs to CD4 or to other membrane proteins, such as MHC class I, did not reveal the presence of JAK2 (Fig. 3A), ruling out nonspecific protein association to membrane components under our experimental conditions. The rapid association of JAK2 to the CCR2 receptor suggests a role for this tyrosine kinase in early receptor phosphorylation following ligand stimulation. Anti-JAK1 and -JAK3 Abs were used to test for the presence of other JAK family members associated to the CCR2 receptor with negative results (data not shown).


To confirm JAK pathway involvement in the signaling response through the CCR2 chemokine receptor, we analyzed JAK2 kinase-activated STAT transcription factors in anti-CCR2 immunoprecipitates. STAT3, but not STAT5, associates to the receptor complex in response to MCP-1 (Fig. 4B); the association of STAT3 correlates in time with JAK2 phosphorylation and binding. Furthermore, this STAT3 is tyrosine phosphorylated, indicating its activation (Fig. 4C). It thus appears that CCR2 receptor activation

induces receptor and JAK2 phosphorylation and STAT3 binding. The MCP-1-triggered tyrosine phosphorylation of the CCR2 receptor is independent of PTX-sensitive G proteins (Fig. 3B); PTX also had no effect on JAK2 kinase binding to the receptor (Fig. 3C). Whereas MCP-1-induced association of JAK2 to the CCR2 receptor is not impeded by this toxin, PTX blocked JAK2 kinase dissociation from the receptor (Fig. 3C), implying that PTX-sensitive G protein activation is important in the recycling of the JAK2/STAT3 receptor complex.

MCP-1-promoted Ca^{2+} influx and cell mobilization were blocked when cells were pretreated with the specific JAK2 kinase inhibitor, tyrphostin B42 (29) (Fig. 5, A and B), indicating the importance of this kinase in early signaling events. As expected, B42 treatment inhibits $\text{G}\alpha_i$ association to the receptor, in accordance with the role of this G protein in GPCR-mediated effects (Fig. 5C). Tyrphostin treatment was not toxic to Mono Mac 1 cells, as shown by cell cycle analysis using propidium iodide incorporation (not shown).

Despite the rapid and transient JAK2-mediated CCR2 tyrosine phosphorylation, phosphorylated CCR2 can be observed long after maximum JAK2 association, thus implicating other tyrosine kinases, as described for RANTES activation of human T cells (25).

FIGURE 5. A specific JAK2 inhibitor, tyrphostin B42, blocks MCP-1-induced responses. **A**, Calcium influx was promoted by 5 nM MCP-1 in Fluo-3-AM-loaded Mono Mac 1 cells, untreated or treated with tyrphostin B42 or tyrphostin A1, and measured at 525 nm in a flow cytometer. The result of one of three experiments performed is shown. Equivalent Fluo-3, AM loading was controlled as described in *Materials and Methods*. **B**, Mono Mac 1 cells, untreated (\square) or incubated with 25 μ M tyrphostin B42 (▨) or control tyrphostin A1 (\blacksquare) for 12 h and allowed to migrate in porous cell culture inserts in the presence of 5 nM MCP-1 in the lower chamber. Cells that migrated to the lower chamber were counted and expressed as a migration index, calculated as the x-fold increase in the migration observed over the negative control (PBS). Data represent the mean of triplicate determinations, with the SD indicated. **C**, B42-treated Mono Mac 1 cells were stimulated with MCP-1, lysed, and immunoprecipitated, and Western blot was analyzed as described in the legend to Figure 1B. As a positive control, Mono Mac 1 cell lysates were tested in Western blot with the same anti- $G\alpha_i$ Ab. CCR2 protein loading was controlled by stripping and reprobing membranes with MCP-1R05 mAb. The arrow shows the position of $G\alpha_i$.



The Tyr¹³⁹ residue of CCR2 is critical in MCP-1-activated signaling

To further investigate the significance of MCP-1-induced CCR2 receptor tyrosine phosphorylation, the CCR2B receptor Tyr¹³⁹Phe mutant CCR2BY139F was constructed, expressed in HEK293 cells, and its response to MCP-1 analyzed. Tyr¹³⁹ is located in the second intracellular loop and forms part of the DRY sequence, a highly conserved motif in GPCR that is essential for agonist-mediated receptor activation (35); it is the only intracellular tyrosine conserved in the functionally homologous CCR2A receptor (33). Wild-type and CCR2BY139F mutant receptor expression were identical in stably transfected HEK293 cells as assessed by flow cytometry (Fig. 6A), and both receptor forms bind MCP-1 equally well (not shown). MCP-1 induces Ca²⁺ mobilization in CCR2B wild-type HEK293 cells, but not in CCR2BY139F mutant or in mock-transfected HEK293 cells (Fig. 6B). Phosphorylation of the mutant receptors was analyzed; in contrast to the wild-type receptor, the CCR2BY139F mutant is unphosphorylated in tyrosine residues following MCP-1 binding (Fig. 7, *upper panel*) and cannot trigger JAK2 phosphorylation or association to the receptor (Fig. 7, *middle panel*). Finally, MCP-1 promotes $G\alpha_i$ association to the CCR2B receptor, but not to the mutant CCR2BY139F receptor (Fig. 7,

lower panel). These results clearly demonstrate the relevance of JAK2 phosphorylation, as well as of JAK2 and $G\alpha_i$ association in the functional response to MCP-1.

Discussion

Transendothelial leukocyte migration into inflammation sites is a complex process in which several cell surface molecules, including the selectin family of adhesion molecules, integrins, and their ligands, act in concert to regulate cell migration. Soluble mediators, mainly chemokines, are also central both in activating and directing specific leukocyte subsets to target tissues. It is known that chemokines bind to GPCR and induce changes in intracellular cAMP levels, activate phospholipases, and increase tyrosine phosphorylation. The initial steps in receptor activation that lead to the wide variety of chemokine-triggered cellular responses are still, however, not known.

MCP-1 was first described as a potent chemoattractant for monocytes and binds the CCR2 and the CCR4 chemokine receptors (36). In CCR2-expressing cells, MCP-1 binding promotes Ca²⁺ mobilization and transmigration, processes that are blocked by PTX treatment but not by CTX (21). Using a human monocytic cell line, Mono Mac 1, which also responds to MCP-1 and CCR2-specific mAb (15, 30), we have demonstrated that G_i




FIGURE 6. CCR2B receptor expression in HEK293 cells. Cells were stably transfected with human CCR2B and mutant human CCR2BY139F cDNA. **A**, Flow cytometry analysis of anti-CCR2 mAb MCP-1R03 or MCP-1R05 (as indicated) binding to representative CCR2B or CCR2BY139F clones, compared with that of a control mAb (shaded peak). **B**, MCP-1-induced Ca^{2+} influx in CCR2B and CCR2BY139F cells was determined by flow cytometry at 525 nm. The result depicts one of three experiments performed with selected clones.

associates rapidly (within 30 s) to CCR2 after MCP-1 activation. This confirms previous data indicating that other chemokine receptors, such as IL-8R, bind $\text{G}\alpha_i$ in response to IL-8 (37) and extends the observation to members of the CC family of chemokine receptors.

Despite G_i binding to the CCR2 receptor and its implications in signaling events subsequent to MCP-1 binding, we cannot exclude the participation of other G proteins in the signaling activated by this chemokine. It is reasonable to consider that the cellular response of a given chemokine receptor varies depending on the cell in which it is expressed. This is presumably due to the availability of specific G protein subunits and other downstream effector molecules. It has thus recently been demonstrated that the association of chemokine receptors to different G proteins depends on the receptor and the cell line studied (28).

Chemokines also promote an increase in tyrosine kinase activity; it has recently been shown that RANTES induces activation and assembly of macromolecular focal adhesion complexes and provokes T lymphocyte homotypic adhesion by phosphorylation and association of $\text{p}125^{\text{FAK}}$ and ZAP-70 (25).

Even more interesting is the identification of the phosphorylated CCR2 receptor itself. Several assays performed to identify the kinase responsible for CCR2 receptor phosphorylation led to the conclusion that JAK2 causes early receptor activation. Both JAK2 association and CCR2 tyrosine phosphorylation occur even in the presence of PTX, indicating no G_i participation in this process; JAK2 dissociation was not observed under these conditions, suggesting an active participation of G_i pathways in uncoupling JAK2 from the receptor. In response to MCP-1, this kinase is phosphorylated as soon as 30 s after binding, indicating that JAK2 activation is simultaneous with its association to CCR2.

Furthermore, STAT3, but not STAT5, is associated to the CCR2 following MCP-1 activation in accordance with the role assigned to the JAK tyrosine kinases in transducing signals from hemopoietic growth factor receptors (38). In these receptors, the activation and association of JAK kinase to the receptor creates docking sites for SH_2 -containing proteins such as STAT, leading to their phosphorylation and activation of gene transcription.

Neither MCP-1-induced, PTX-sensitive G protein-mediated physiologic effects nor $\text{G}\alpha_i$ association to CCR2 were observed after treatment of Mono Mac 1 cells with the JAK2-specific inhibitor tyrphostin B42. This is not the case when cells are treated with other tyrphostins, indicating that inhibition of JAK2 kinase activity abolishes the association and activation of the G proteins responsible for this response. This result and the JAK2 association to the CCR2 receptor in PTX-treated cells imply that the first event after MCP-1 binding to the CCR2 in Mono Mac 1 cells is association of the JAK2 kinase. The conformational changes promoted by both ligand interaction and tyrosine kinase association induce G_i protein association to its binding site, probably located in the second intracellular loop, as is the case for the IL-8R (37).

To determine which CCR2B receptor Tyr residue is involved in JAK2 kinase association, and as Tyr¹³⁹ is the only intracellular tyrosine conserved in the functionally homologous CCR2A receptor (33), we generated a CCR2BY139F receptor by point mutation. Although this mutated receptor binds MCP-1 as well as does the wild-type receptor, it does not elicit MCP-1-triggered functional responses such as Ca^{2+} mobilization, cell migration, or CCR2B tyrosine phosphorylation. This lack of response is due to abolition of the association to the receptor by the JAK2 kinase and then of the G_i protein. The tyrosine at position 139 is part of the conserved DRY motif present in most chemokine receptors. Earlier studies characterized the critical roles of arginine and aspartic acid in the DRY motif, implicated in G protein-mediated signaling in other




FIGURE 7. CCR2B tyrosine phosphorylation and JAK2 and $G\alpha_i$ association in HEK293 cells. **A**, Representative CCR2B or CCR2BY139F clones, unstimulated or MCP-1 stimulated for 30 s, were lysed and immunoprecipitated with anti-PTyr PY20 mAb and tested in Western blot with anti-CCR2 Ab. Equivalence in immunoprecipitate protein amounts was controlled by reprobing Western blots with anti-PTyr (not shown). **B**, Clones as described above were immunoprecipitated with anti-CCR2 and blotted with anti-JAK2 Ab. A control is shown of CCR2-transfected HEK293 cell lysate immunoprecipitated with anti-MHC class I Ab and analyzed with anti-JAK2 Ab. CCR2 protein loading was controlled by stripping and reprobing membranes with mAb MCP-1R05. **C**, Clones as described above were immunoprecipitated with anti-CCR2 and tested in Western blot with anti- $G\alpha_i$ Ab. The protein loading control is the same as described for **B**. The arrow shows the position of $G\alpha_i$.

GPCR (35). The importance of the tyrosine in G protein activation is demonstrated here, as the Tyr¹³⁹Phe mutation also impaired Ca²⁺ mobilization triggered by MCP-1 binding and G_i association to the CCR2B receptor.

These data fit a model in which G_i association to the chemokine is a consequence of conformational changes promoted by both ligand interaction and JAK2 activation. If this is the case, a mutant form with a constitutively associated G_i protein should activate signaling in response to the chemokine. This occurs, in fact, in another chemotactic peptide receptor belonging to the GPCR family, the C5a receptor (39), in which phenylalanine replaces the tyrosine in the DRY motif, while its capacity to activate G_i signaling remains intact.

Phosphorylation of the DRY motif tyrosine in a β_2 -adrenergic receptor has also recently been suggested as linking this receptor to the insulin-like growth factor (IGF)-1 receptor pathway (40). In accordance with recent reports suggesting JAK pathway modulation by other GPCR (41), as well as agonist-induced β -adrenergic receptor dimerization (42), we suggest that receptor dimerization may be a primary event following agonist binding to G protein-coupled receptors. We thus amplify earlier interpretations by suggesting that the inability of CCR2BY139F to promote G_i protein association results from the failure of the receptor to dimerize. Since signaling by G protein-coupled receptors leads to calcium mobilization within seconds, we postulate that the ligand promotes a conformational change that stabilizes the receptor dimers.

Finally, the dimerization hypothesis may also be helpful in understanding how chemokines prevent HIV-1 infection, as we conjecture that receptor dimerization prevents HIV-1 interaction with the chemokine receptor. Recent reports indicate that heterodimerization between CCR5 and its mutant CCR5 Δ 32 is a molecular explanation for the delayed onset of AIDS in heterozygous CCR5/crr5 Δ 32 individuals (43). Our results also extend the model of cytokine receptor signaling to the chemokines, which are functionally related molecules although they use structurally unrelated receptors.

Acknowledgments

We thank L. R.-Borlado for helpful advice and discussions; M. Barradas for skillful help in establishing stably transfected cell lines; Drs. J. Paz-Ares and E. Montoya for critical reading of the manuscript; and C. Bastos and C. Mark for secretarial and editorial assistance, respectively.

References

- Murphy, P. M. 1994. The molecular biology of leukocyte chemoattractant receptors. *Annu. Rev. Immunol.* 12:593.
- Hedrick, J. A., and A. Zlotnik. 1996. Chemokines and lymphocyte biology. *Curr. Opin. Immunol.* 8:343.
- Howard, O. M. Z., A. Ben-Baruch, and J. J. Oppenheim. 1996. Chemokines: progress toward identifying molecular targets for therapeutic agents. *Trends Biotechnol.* 14:46.
- Baggiolini, M., and C. A. Dahinden. 1994. CC Chemokines in allergic inflammation. *Immunol. Today* 15:127.
- Kunkel, S. L., R. M. Strieter, I. J. D. Lindley, and J. Westwick. 1995. Chemokines: new ligands, receptors and activities. *Immunol. Today* 16:559.
- Downey, G. P. 1994. Mechanisms of leukocyte motility and chemotaxis. *Curr. Opin. Immunol.* 6:113.
- Schall, T. J. 1994. The Chemokines. In *The Cytokine Handbook*. A. W. Thompson, ed. Academic Press, London, pp. 181-272.
- Kelner, G. S., J. Kennedy, K. B. Bacon, S. Kleyensteuber, D. A. Largaespada, N. A. Jenkins, N. G. Copeland, J. F. Bazan, K. W. Moore, T. J. Schall, and A. Zlotnik. 1994. Lymphotactin: a cytokine that represents a new class of chemokine. *Science* 266:1395.
- Bazan, J. F., K. B. Bacon, G. Hardiman, W. Wang, K. Soo, D. Rossi, D. R. Greaves, A. Zlotnik, and T. J. Schall. 1997. A new class of membrane-bound chemokine with a CX₃C motif. *Nature* 385:640.
- Matsushima, K., C. Larsen, G. C. DuBois, and J. J. Oppenheim. 1989. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. *J. Exp. Med.* 169:1485.

11. Sylvester, J., A. F. Suffredini, A. J. Boujoukos, G. D. Martich, R. L. Danner, T. Yochimura, and E. J. Leonard. 1993. Neutrophil attractant protein-A1 and monocyte chemoattractant protein-1 in human serum. *J. Immunol.* 151:3292.
12. Van Damme, J., P. Proost, W. Put, S. Arens, J.-P. Lenaerts, R. Conings, G. Opdemakker, H. Heremans, and A. Billau. 1994. Induction of monocyte chemotactic proteins MCP-1 and MCP-2 in human fibroblasts and leukocytes by cytokines and cytokine inducers. *J. Immunol.* 152:5495.
13. Carr, M. W., S. J. Roth, E. Luther, S. S. Rose, and T. A. Springer. 1994. Monocyte chemoattractant protein-1 acts as a T-lymphocyte. *Proc. Natl. Acad. Sci. USA* 91:3652.
14. Flory, C. M., M. L. Jones, and J. S. Warren. 1993. Pulmonary granuloma formation in the rat is partially dependent on monocyte chemoattractant protein 1. *Lab. Invest.* 69:396.
15. Frade, J. M. R., M. Llorente, M. Mellado, J. Alcamí, J. C. Gutierrez-Ramos, A. Zaballos, G. del Real, and C. Martinez-A. 1997. The amino-terminal domain of the CCR2 chemokine receptor acts as coreceptor for HIV-1 infection. *J. Clin. Invest.* 100:1.
16. Schröder, A. E., A. Greiner, C. Seyfert, and C. Berek. 1996. Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. *Proc. Natl. Acad. Sci. USA* 93:221.
17. Bossink, A. W. J., L. Paemaen, P. M. Jansen, C. E. Hack, L. G. Thijs, and J. Van Damme. 1995. Plasma levels of the chemokines monocyte chemotactic proteins-1 and -2 are elevated in human sepsis. *Blood* 86:3841.
18. Yoshida, R., T. Imai, K. Hieshima, J. Kusuda, M. Baba, M. Kitaura, M. Nishimura, M. Kakizaki, H. Nomiya, and O. Yoshie. 1997. Molecular cloning of a novel human CC chemokine EBI1-ligand chemokine that is a specific functional ligand for EBI1, CCR7. *J. Biol. Chem.* 272:13803.
19. Gayle, R. B., III, P. R. Sleath, S. Srinivasan, C. W. Birks, K. S. Weerawarna, D. P. Cerreti, C. J. Kozlosky, N. Nelson, T. Vanden Boss, and M. P. Beckmann. 1993. Importance of the amino terminus of the interleukin-8 receptor in ligand interactions. *J. Biol. Chem.* 268:7283.
20. Monteclaro, F. S., and I. F. Charo. 1996. The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1 α receptor, confers chemokine selectivity: evidence for a two-step mechanism for MCP-1 receptor activation. *J. Biol. Chem.* 271:19084.
21. Bokoch, G. M. 1995. Chemoattractant signaling and leukocyte activation. *Blood* 86:1649.
22. Amatruda, T. T., N. P. Gerard, C. Gerard, and M. I. Simon. 1993. Specific interactions of chemoattractant receptors with G-proteins. *J. Biol. Chem.* 268:10139.
23. Ahmed, M. U., K. Hazeki, O. Hazeki, T. Katada, and M. Ui. 1995. Cyclic AMP-increasing agents interfere with chemoattractant-induced respiratory burst in neutrophils as a result of the inhibition of phosphatidylinositol 3-kinase rather than receptor-operated Ca²⁺ influx. *J. Biol. Chem.* 270:23816.
24. Bacon, K. B., L. Flores-Romo, P. F. Life, D. D. Taub, B. A. Premack, S. J. Arkininstall, T. N. C. Wells, T. J. Schall, and C. A. Power. 1995. IL-8-induced signal transduction in T lymphocytes involves receptor-mediated activation of phospholipases C and D. *J. Immunol.* 154:3654.
25. Bacon, K. B., M. C. Szabo, H. Yssel, J. B. Bolen, and T. J. Schall. 1996. RANTES induces tyrosine kinase activity of stably complexed p125^{FAK} and ZAP-70 in human T cells. *J. Exp. Med.* 184:873.
26. Worthen, G. S., N. Avdi, A. M. Buhl, N. Suzuki, and G. L. Johnson. 1994. FMLP activates Ras and Raf in human neutrophils: potential role in activation of MAP kinase. *J. Clin. Invest.* 94:815.
27. Jones, S. A., B. Moser, and M. Thelen. 1995. A comparison of post-receptor signal transduction events in Jurkat cells transfected with either IL-8R1 or IL-8R2 chemokine mediated activation of p42/p44 MAP-kinase (ERK-2). *FEBS Lett.* 364:211.
28. Arai, H., and I. F. Charo. 1996. Differential regulation of G-protein-mediated signaling by chemokine receptors. *J. Biol. Chem.* 271:21814.
29. Meydan, N., T. Grunberger, H. Dadi, M. Shahar, E. Arpaia, Z. Lapidot, J. S. Leeder, M. Freedman, A. Cohen, A. Gazit, A. Levitzki, and C. M. Roifman. 1996. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. *Nature* 379:645.
30. Frade, J. M. R., M. Mellado, G. del Real, J. C. Gutierrez-Ramos, P. Lind, and C. Martinez-A. 1997. Characterization of the CCR2 chemokine receptor: functional CCR2 receptor expression in B cells. *J. Immunol.* 159:5576.
31. Carrera, A. C., S.-B. Wee, T. M. Roberts, and D. M. Pardoll. 1992. Selective association between MHC class I-restricted T cell receptors, CDS, and activated tyrosine kinases on thymocytes undergoing positive selection. *J. Immunol.* 149:3142.
32. Mellado, M., J. M. Rodríguez-Frade, L. Kremer, C. von Kobbe, A. Martín de Ana, I. Mérida, and C. Martínez-A. 1997. Conformational changes required in the human growth hormone receptor for growth hormone signaling. *J. Biol. Chem.* 272:9189.
33. Charo, I. F., S. J. Myers, A. Herman, C. Franci, A. J. Connolly, and S. R. Coughlin. 1994. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. *Proc. Natl. Acad. Sci. USA* 91:2752.
34. del Pozo, M. A., P. Sanchez-Mateos, and F. Sanchez-Madrid. 1996. Cellular polarization induced by chemokines: a mechanism for leukocyte recruitment? *Immunology Today* 17, 127.
35. Scheer, A., F. Fanelli, T. Costa, P. G. De Benedetti, and S. Cotecchia. 1996. Constitutively active mutants of the alpha 1 β -adrenergic receptor: role of highly conserved polar amino acids in receptor activation. *EMBO J.* 15:3566.
36. Power, C. A., A. Meyer, K. Nemeth, K. B. Bacon, A. J. Hoogewerf, A. E. I. Proudfoot, and T. N. C. Wells. 1995. Molecular cloning and functional expression of a novel CC chemokine receptor cDNA from a human basophilic cell line. *J. Biol. Chem.* 270:19495.
37. Damaj, B. B., S. R. McColl, K. Neote, N. Songquing, K. T. Ogborn, C. A. Hebert, and P. H. Naccache. 1996. Identification of G-protein binding sites of the human interleukin-8 receptors by functional mapping of the intracellular loops. *FASEB J.* 12:1426.
38. Lütticken, C., U. M. Wegenka, J. Yuan, J. Buschmann, C. Schindler, A. Ziemiecki, A. J. Harpur, A. F. Wilks, K. Yasukawa, T. Taga, T. Kishimoto, G. Barbieri, S. Pellegrin, M. Sendtner, P. C. Heinrich, and F. Horn. 1994. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. *Science* 263:89.
39. Siciliano, S. J., T. E. Rollins, and M. S. Springer. 1990. Interaction between the C5a receptor and Gi in both the membrane-bound and detergent-solubilized states. *J. Biol. Chem.* 265:19568.
40. Karoor, V., and C. C. Malbon. 1996. Insulin-like growth factor receptor-1 stimulates phosphorylation of the beta2-adrenergic receptor in vivo on sites distinct from those phosphorylated in response to insulin. *J. Biol. Chem.* 271:29347.
41. Marrero, M. B., B. Schieffer, W. G. Paxton, L. H. Eerdt, B. C. Berk, P. Delafontaine, and K. E. Bernstein. 1995. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. *Nature* 375:247.
42. Hebert, T. E., S. Moffett, J. P. Morello, T. P. Loisel, D. G. Bichet, C. Barret, and M. Bouvier. 1996. A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. *J. Biol. Chem.* 271:16384.
43. Benkirane, M., D.-Y. Jin, R. F. Chun, R. A. Koup, and K.-T. Jeang. 1997. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5 Δ 32. *J. Biol. Chem.* 272:30602.